What Is 2'-5'-oligoadenylate synthetase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2'-5'-oligoadenylate synthetase (OAS) is an enzyme activated by interferon during viral infections, first identified in 1979. It synthesizes 2'-5'-oligoadenylates that activate RNase L to degrade viral RNA, playing a key role in innate immunity. Humans have four OAS genes: OAS1, OAS2, OAS3, and OASL.

Key Facts

2'-5'-oligoadenylate synthetase was first discovered in 1979 by Reis and colleagues.
OAS enzymes are induced by type I interferons (IFN-α and IFN-β) during viral infection.
The OAS1 gene is located on human chromosome 12q24.13.
OAS activation leads to the production of 2'-5'-linked oligoadenylates up to 10 nucleotides long.
RNase L, activated by 2'-5'-oligoadenylates, degrades both viral and cellular single-stranded RNA.

Overview

2'-5'-oligoadenylate synthetase (OAS) is a critical enzyme in the human innate immune response, particularly against RNA viruses. It functions as part of the interferon signaling pathway, where its expression is upregulated in response to viral infection to limit viral replication.

OAS proteins are encoded by a family of genes in humans, including OAS1, OAS2, OAS3, and OASL, each with distinct tissue expression and functional roles. The enzyme becomes activated upon binding double-stranded RNA (dsRNA), a molecular signature of many viral infections.

Discovery: OAS was first identified in 1979 by Reis and colleagues during studies on interferon-induced antiviral mechanisms, marking a milestone in immunology.
Gene location: The OAS1 gene is located on chromosome 12q24.13, within a cluster of OAS-related genes that evolved through gene duplication events.
Interferon induction: Type I interferons (IFN-α and IFN-β) induce OAS expression, enhancing cellular antiviral defenses within hours of infection.
Enzyme class: OAS belongs to the nucleotidyltransferase family, catalyzing the polymerization of ATP into 2'-5'-linked oligoadenylates.
Structure: OAS proteins contain a nucleotidyltransferase domain and one or more dsRNA-binding domains, essential for activation during viral detection.

How It Works

The mechanism of 2'-5'-oligoadenylate synthetase involves a tightly regulated cascade initiated by viral RNA detection and culminating in RNA degradation. This pathway is a cornerstone of the interferon response system.

Double-stranded RNA (dsRNA): Viral replication often produces dsRNA, which acts as a pathogen-associated molecular pattern (PAMP) detected by cellular sensors. This triggers OAS activation.
OAS activation: Upon binding dsRNA, OAS undergoes a conformational change that enables its enzymatic activity, allowing it to synthesize 2'-5'-oligoadenylates from ATP.
2'-5'-oligoadenylate production: OAS generates short chains of adenylate residues linked by 2'-5' phosphodiester bonds, typically 3–10 nucleotides long, which are not found in normal cellular metabolism.
RNase L binding: These 2'-5'-oligoadenylates bind to and activate RNase L, a latent endoribonuclease present in the cytoplasm of most mammalian cells.
RNA degradation: Activated RNase L cleaves single-stranded RNA, including viral genomes and host mRNA, thereby inhibiting viral replication and spreading the antiviral state.
Feedback loop: RNA fragments generated by RNase L can further stimulate RIG-I-like receptors, amplifying interferon production and enhancing immune surveillance.

Comparison at a Glance

Human OAS isoforms differ in size, structure, and activity. The following table compares key features:

OAS Type	Size (kDa)	ATP Units Produced	Gene Location	Key Function
OAS1	42	2–4	12q24.13	Initiates 2-5A synthesis, activates RNase L
OAS2	69	4–5	12q24.13	Higher-order oligomer synthesis, sustained response
OAS3	100	6–10	12q24.13	Most potent activator of RNase L
OASL	56	None (pseudosynthetase)	12q24.13	Enhances RIG-I signaling, no 2-5A production
Mouse OAS1b	42	None	Chromosome 5	Confers flavivirus resistance, no enzymatic activity

These isoforms illustrate evolutionary adaptation in antiviral defense. While OAS1, OAS2, and OAS3 produce 2'-5'-oligoadenylates, OASL lacks synthetase activity but contributes to immune signaling, showing functional divergence.

Why It Matters

Understanding OAS function has broad implications for virology, immunology, and therapeutic development. Its role in innate immunity makes it a key target for antiviral strategies and disease susceptibility research.

Viral resistance: Genetic variants in OAS1 are linked to resistance against flaviviruses like West Nile virus, with specific SNPs reducing infection risk by up to 40%.
Autoimmune disease: Dysregulated OAS activity is associated with Aicardi-Goutières syndrome, a rare disorder mimicking congenital viral infection.
Therapeutic target: Enhancing OAS pathway activity could lead to broad-spectrum antiviral drugs effective against RNA viruses like SARS-CoV-2.
COVID-19 research: OAS1 expression levels correlate with SARS-CoV-2 outcomes, with certain haplotypes linked to reduced severity.
Evolutionary insight: The OAS gene cluster shows strong positive selection, indicating long-term host-pathogen conflict shaping human immunity.
Biomarker potential: OAS1 mRNA levels are used as a biomarker for interferon response in clinical studies of autoimmune and infectious diseases.

Continued research into OAS enzymes promises to uncover new aspects of antiviral defense and improve treatments for viral infections and immune disorders.